

WEST Search History

DATE: Monday, March 19, 2007

11/203,587

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		DB=TDBD,DWPI,JPAB,EPAB,USOC,USPT,PGPB; PLUR=YES; OP=OR	
		(DELTA-AMINO-GAMMA-HYDROXY-OMEGA-ARYLALKANOIC DELTA-AMINO-GAMMA-HYDROXY-OMEGA-ARYL-ALKANOIC DELTA-AMINO-GAMMA-HYDROXY-OMEGA-ARYL-ALKA-NOIC DELTA-AMINO-GAMMA-HYDROXY-OMEGA-ARYL- ALKANECARBOXAMIDES DELTA-AMINO-GAMMA-HYDROXY- OMEGA-ARYL-ALKANECARBOX-AMIDES DELTA-AMINO-GAMMA- HYDROXY-OMEGA-ARYL-ALKAN-ECARBOXAMIDES DELTA-AMINO- GAMMA-HYDROXY-OMEGA-ARYL-ALKAN-ECARBOX-AMIDES DELTA-AMINO-GAMMA-HYDROXY-ALPHA-ARYL-ALKAN- ECARBOXAMIDES DELTA-AMINO-GAMMA-HYDROXY-ALPHA-ARYL- ALKANECARBOXAMIDES DELTA-AMINO-GAMMAHYDROXY- OMEGA-ARYLALKANECARBOXAMIDES)!	32
<input type="checkbox"/>	L1		
<input type="checkbox"/>	L2	(DELTA-AMINO-GAMMA-HYDROXY-OMEGA-A-RYL-ALKANOIC)!	1
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR	
<input type="checkbox"/>	L3	l2 and l1	1
<input type="checkbox"/>	L4	l2 or l1	32
<input type="checkbox"/>	L5	l4 and (carr\$ or capsul\$ or \$emulsion or emulsified or emulsification or emulsifier or microemulsion or micro-emulsion or lipo\$)	10
		DB=EPAB; PLUR=YES; OP=OR	
<input type="checkbox"/>	L6	EP-1729748-A1.did.	1

END OF SEARCH HISTORY

Publication Number	Application Number	Doc Kind	Pages	Country
2005058291	2004014433	A1	27	WO
Publication Date	Application Date	Emperor Code	<input type="button" value="OK"/> <input type="button" value="Print Detail"/>	
Jun 30, 2005	Dec 17, 2004			
Priority Number	Inventor			
53156203	OTTINGER ISABEL			

Int'l Classification	Patent Applicant
A61K31/00	NOVARTIS AG

Title Of Invention
MICROEMULSION PRECONCENTRATE COMPRISING A RENIN INHIBITOR PRECONCENTRE EN MICROEMULSION COMPRENANT UN INHIBITEUR DE RENINE

WEST Search History

DATE: Monday, March 19, 2007

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L2	renin near25 (blocker or modulator or inactivat\$ or modulat\$ or block\$ or inhibit\$ or antagonist\$)	5622
<input type="checkbox"/>	L3	L2 and \$emulsion	843
<input type="checkbox"/>	L4	L3 and (peg or polyethylene\$ or peg300 or peg-300)	649
<input type="checkbox"/>	L5	L4 and (\$surfactant or surfactant\$)	352
<input type="checkbox"/>	L6	L5 and (poly-sorbat\$ or polysorbat\$ or macrogol\$ or etpgs or e-tpgs or caster or casteroil or caster-oil)	100
<input type="checkbox"/>	L7	L6 and (fatty or fattyacid or fatty-acid)	78
<input type="checkbox"/>	L8	L7 and oil	78
<input type="checkbox"/>	L9	renin.ti,ab,clm.	2664
<input type="checkbox"/>	L10	L9 and l2	2231
<input type="checkbox"/>	L11	l2.ti,ab,clm.	2145
<input type="checkbox"/>	L12	L11 and \$alkanoic	150

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 32 of 32 returned.**

-
- ☐ 1. [20070049616](#). 23 Aug 06. 01 Mar 07. Organic compounds. Ksander; Gary Michael, et al. 514/303; 514/393 546/119 548/302.7 A61K31/4188 20070101 A61K31/4745 20070101 C07D471/02 20060101
-
- ☐ 2. [20060041169](#). 21 Oct 05. 23 Feb 06. PREPARATION OF N-SUBSTITUTED 2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES. Herold; Peter, et al. 564/161; C07C231/12 20060101
-
- ☐ 3. [20040132148](#). 14 Nov 03. 08 Jul 04. Process for the preparation of substituted carboxylic esters. Herold, Peter, et al. 435/135; 435/136 C12P007/62 C12P007/40.
-
- ☐ 4. [20040092766](#). 03 Jan 03. 13 May 04. Process for the preparation of (r)-2-alkyl-3-phenyl-1-propanols. Stutz, Stefan, et al. 562/532; C07C051/16 C07C051/235.
-
- ☐ 5. [20030176717](#). 15 Jan 03. 18 Sep 03. Process for the preparation of aryloctanoyl amides. Bellus, Daniel, et al. 554/51; C11C003/00 C07C237/20.
-
- ☐ 6. [20030149303](#). 03 Jan 03. 07 Aug 03. Process for the preparation of substituted octanoyl amides. Stutz, Stefan, et al. 564/164; 549/321 C07C233/53 C07D305/12.
-
- ☐ 7. [20030139625](#). 02 Jan 03. 24 Jul 03. Preparation of (r -2-alkyl-3-phenylpropionic acids. Stutz, Stefan, et al. 562/496; C07C053/134 C07C057/30.
-
- ☐ 8. [20020082302](#). 14 Dec 01. 27 Jun 02. Process for the preparation of aryloctanoyl amides. Bellus, Daniel, et al. 514/620; 514/534 554/51 A61K031/24 A61K031/165.
-
- ☐ 9. [7153675](#). 26 Apr 02; 26 Dec 06. Process for the preparation of substituted carboxylic esters. Herold; Peter, et al. 435/135; 435/136 560/129. C07C69/02 20060101 C12P7/40 20060101 C12P7/62 20060101 .
-
- ☐ 10. [7132569](#). 21 Oct 05; 07 Nov 06. Preparation of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amides. Herold; Peter, et al. 564/161; C07C233/04 20060101 C07C233/05 20060101 .
-
- ☐ 11. [7009078](#). 13 Jul 00; 07 Mar 06. Production of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides. Herold; Peter, et al. 564/161; C07C233/04 20060101 C07C233/05 20060101 .
-
- ☐ 12. [6881868](#). 03 Jan 03; 19 Apr 05. Process for the preparation of (R)-2-alkyl-3-phenyl-1-propanols. Stutz; Stefan, et al. 568/608; 560/55 560/60 560/64 568/610 568/630 568/648 568/649 568/651 568/656 568/658 568/715 568/812. C07C041/18 .
-
- ☐ 13. [6800769](#). 24 Jan 03; 05 Oct 04. Process for the preparation of substituted octanoyl amides. Stutz; Stefan, et al. 552/11; 554/36 554/51 554/62. C07C247/06 .
-
- ☐ 14. [6777574](#). 29 Jan 02; 17 Aug 04. 2-alkyl-5-halogen-pent-4-ene carboxylic acids and their production. Herold; Peter, et al. 560/129; 560/205 560/219 562/400 562/507 562/510. C07C069/00 .
-

- ☐ 15. 6730798. 03 Jan 03; 04 May 04. Process for the preparation of substituted octanoyl amides. Stutz; Stefan, et al. 549/323; 549/561 560/104 562/471 562/495 564/191. C07D305/12 .
-
- ☐ 16. 6683206. 02 Jan 03; 27 Jan 04. Preparation of (R -2-alkyl-3-phenylpropionic acids. Stutz; Stefan, et al. 562/465; 502/162 556/21 562/450. C07C063/64 C07C229/00 .
-
- ☐ 17. 6670507. 15 Jan 03; 30 Dec 03. Process for the preparation of aryloctanoyl amides. Bellus; Daniel, et al. 564/134; 548/216 549/321 556/410 564/165. C07C231/02 C07C231/10 C07C231/16 C07C263/02 C07C307/12 .
-
- ☐ 18. 5705658. 14 Feb 97; 06 Jan 98. Azido containing tetrahydro furan compounds. Goschke; Richard, et al. 549/321; 544/168. C07D307/33 .
-
- ☐ 19. 5659065. 04 Apr 95; 19 Aug 97. Alpha-aminoalkanoic acids and reduction products. Goschke; Richard. 560/29; 544/111 544/122 544/146 544/162 544/165 544/242 544/296 544/359 544/360 544/379 544/398 544/59 544/60 546/174 546/176 546/208 546/210 546/212 546/232 546/270.4 546/272.7 546/276.4 546/280.4 546/283.4 546/293 546/334 546/335 548/146 548/339 .1 548/518 548/527 548/566 549/362 560/24 560/27 560/38 568/423 568/424 568/704 568/706. C07C219/28 C07C223/02 C07C229/06 C07C229/08 C07C229/10 C07C229/36 .
-
- ☐ 20. 5654445. 02 Jul 96; 05 Aug 97. .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acids. Goschke; Richard, et al. 549/321; 548/215 554/110. C07D307/33 C07F007/18 .
-
- ☐ 21. 5646143. 25 Jul 96; 08 Jul 97. .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides. Goschke; Richard, et al. 514/233.8; 544/148 549/362 549/441 554/55. A61K031/335 A61K031/535 C07D317/64 C07D413/12 .
-
- ☐ 22. 5627182. 25 Jul 96; 06 May 97. .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides. Goschke; Richard, et al. 514/237.8; 514/620 544/168 544/58.2 546/226 548/550 554/43 554/54 554/55 554/58. A61K031/165 A61K031/535 C07C237/20 C07D293/14 .
-
- ☐ 23. 5606078. 04 Apr 95; 25 Feb 97. 3,5-Disubstituted tetrahydrofuran-2-ones. Goschke; Richard, et al. 549/321; 549/323. C07D307/33 .
-
- ☐ 24. 5559111. 04 Apr 95; 24 Sep 96. .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides. Goschke; Richard, et al. 514/227.5; 514/620 544/168 544/316 546/216 546/226 546/233 546/337 548/131 548/187 548/204 548/232 548/253 548/319.5 548/338.1 548/546 548/550 554/36 554/37 554/42 554/45. A61K031/165 A61K031/54 C07D237/20 C07D294/14 .
-
- ☐ 25. JP408081430A. 18 Apr 95. 26 Mar 96. NEW DELTA-AMINO-GAMMA-HYDROXY-OMEGA-ARYLALKANOIC ACID AMIDE. GOESCHKE, RICHARD, et al. 384/609. C07C235/34; A61K031/16 A61K031/165 A61K031/215 A61K031/27 A61K031/275 A61K031/335 A61K031/34 A61K031/36 A61K031/395 A61K031/40 A61K031/41 A61K031/415 A61K031/44 A61K031/445 A61K031/505 A61K031/535 A61K031/54 C07C235/36 C07C311/30 C07C317/44 C07C323/10 C07D207/27 C07D207/40 C07D211/32 C07D213/40 C07D213/65 C07D233/64 C07D233/76 C07D239/10 C07D257/04 C07D263/38 C07D265/30 C07D271/06 C07D277/18 C07D295/14 C07D295/18 C07D295/22 C07D307/33 C07D317/64 C07D319/20 C07D521/00 C07F007/18 .
-
- ☐ 26. EP001692095A1. 30 Nov 04. 23 Aug 06. DELTA-AMINO-GAMMA-HYDROXY-OMEGA-ARYL-ALKANOIC ACID AMIDES AND USE AS RENIN INHIBITORS. SELNER, HOLGER, et

al.

☐ 27. [WO2005054177A1](#). 30 Nov 04. 16 Jun 05. DELTA-AMINO-GAMMA-HYDROXY-OMEGA-ARYL-ALKANOIC ACID AMIDES AND USE AS RENIN INHIBITORS. SELLNER, HOLGER, et al. C07C237/22; A61K031/165.

☐ 28. [WO2005051895A1](#). 25 Nov 04. 09 Jun 05. ORGANIC COMPOUNDS. NOVARTIS, AG, et al. C07C237/20; C07D295/02 C07C237/24 C07C271/24 C07C323/29 C07C255/50 C07D319/18 C07D313/08 C07D307/79 C07D207/09 C07D333/08 A61P009/12 A61K031/165 A61K031/325 A61K031/44.

☐ 29. [WO2006069617A](#). Transition metal-catalyzed asymmetric hydrogenation of acrylic acid derivatives is conducted with hydrogen donors using catalyst system comprising ruthenium, rhodium or iridium and chiral phosphorus ligand or achiral phosphine ligand. BOOGERS, J, et al. B01J031/16 B01J031/18 B01J031/24 B01J031/26 B01J031/28 C07B053/00 C07C051/347 C07C051/36 C07C067/00 C07C067/303.

☐ 30. [WO2005058291A](#). Oral composition useful to treat conditions associated with renin activity (e.g. hypertension), comprising delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amide renin inhibitor in absorption enhancing medium. OTTINGER, I. A61K009/107 A61K031/00 A61K031/165 A61P009/00 A61P009/10 A61P009/12 A61P025/00 A61P027/00 A61P027/06.

☐ 31. [WO2005054177A](#). New delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides useful in the manufacture of medicament for the treatment or prevention of hypertension, congestive heart failure, cardiac hypertrophy or cardiac fibrosis. COTTENS, S, et al. A61K031/165 C07C237/00 C07C237/22.

☐ 32. [EP 678500A](#). New amino-alkanoic acid derivs. - useful as intermediates for hydroxylated amino-alkanoic acid amide renin inhibitors. COHEN, N C, et al. A61K031/16 A61K031/165 A61K031/215 A61K031/27 A61K031/275 A61K031/325 A61K031/33 A61K031/335 A61K031/34 A61K031/36 A61K031/365 A61K031/395 A61K031/40 A61K031/41 A61K031/415 A61K031/42 A61K031/425 A61K031/44 A61K031/445 A61K031/495 A61K031/505 A61K031/535 A61K031/54 A61P003/08 A61P009/00 A61P009/12 A61P013/02 A61P025/20 A61P027/02 A61P043/00 C07C000/00 C07C211/03 C07C213/00 C07C215/06 C07C217/04 C07C219/28 C07C223/02 C07C225/00 C07C225/02 C07C225/16 C07C229/06 C07C229/08 C07C229/10 C07C229/36 C07C233/00 C07C235/34 C07C235/36 C07C237/00 C07C237/02 C07C237/20 C07C237/22 C07C237/24 C07C241/08 C07C255/13 C07C255/16 C07C255/20 C07C255/29 C07C255/60 C07C271/06 C07C271/10 C07C271/16 C07C271/18 C07C271/22 C07C311/09 C07C311/30 C07C311/32 C07C311/46 C07C317/00 C07C317/04 C07C317/18 C07C317/28 C07C317/44 C07C323/10 C07C323/12 C07C323/63 C07C333/02 C07D207/26 C07D207/27 C07D207/273 C07D207/33 C07D207/40 C07D211/12 C07D211/32 C07D211/46 C07D211/88 C07D213/30 C07D213/361 C07D213/40 C07D213/56 C07D213/65 C07D213/89 C07D213/891 C07D233/64 C07D233/70 C07D233/76 C07D233/78 C07D237/20 C07D239/10 C07D239/20 C07D241/08 C07D257/02 C07D257/04 C07D263/02 C07D263/06 C07D263/20 C07D263/22 C07D263/26 C07D263/38 C07D265/06 C07D265/30 C07D265/32 C07D271/06 C07D271/22 C07D273/01 C07D277/14 C07D277/18 C07D277/28 C07D279/12 C07D293/14 C07D294/14 C07D295/04 C07D295/13 C07D295/14 C07D295/15 C07D295/18 C07D295/185 C07D295/22 C07D307/00 C07D307/02 C07D307/32 C07D307/33 C07D317/18 C07D317/58 C07D317/64 C07D319/18 C07D319/20 C07D323/12 C07D401/00 C07D403/00 C07D405/00 C07D405/06 C07D407/06 C07D409/00 C07D409/06 C07D413/02 C07D413/06 C07D413/12 C07D413/14 C07D521/00 C07F007/10 C07F007/18 C07M007/00 C07D263/26 C07D413/06.

[Generate Collection](#)[Print](#)

Term	Documents
(2 OR 1).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	32
(L2 OR L1).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	32

[Prev Page](#)[Next Page](#)[Go to Doc#](#)

Summary of Invention Paragraph:

[0002] In EP-A-0 678 503, δ -amino- γ -hydroxy- ω -aryl-alkan-ecarboxamides are described, which exhibit renin-inhibiting properties and could be used as antihypertensive agents in pharmaceutical preparations. The manufacturing procedures described are unsatisfactory in terms of the number of process steps and yields and are not suitable for an industrial process. A disadvantage of these processes is also that the total yields of pure diastereomers that are obtainable are too small.

DOCUMENT-IDENTIFIER: US 7132569 B2

TITLE: Preparation of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amides

PRIOR-PUBLICATION:

DOC-ID

US 20060041169 A1

DATE

February 23, 2006

Brief Summary Text (2):

In the EP-A-0 678 503, .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanecarboxamides are described, which exhibit renin-inhibiting properties and could be used as antihypertensive agents in pharmaceutical preparations. The manufacturing procedures described are unsatisfactory in terms of the number of process steps and yields and are not suitable for an industrial process. A disadvantage of these processes is also that the total obtainable yields of pure diastereomers are too small.

DOCUMENT-IDENTIFIER: US 6777574 B1

TITLE: 2-alkyl-5-halogen-pent-4-ene carboxylic acids and their production

Abstract Text (3):

wherein R.sub.4 is C.sub.1 -C.sub.6 alkyl, Z is chlorine, bromine or iodine, and X is --OH, chloride, bromide or iodide, or X forms an ester group with the carbonyl substituent, as well as salts of carboxylic acids. The compounds are valuable intermediates for the propagation of .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanecarboxamides, which exhibit renin-inhibiting properties and could be used as antihypertensive agents in pharmaceutical preparations.

Brief Summary Text (2):

In the EP-A-0 678 503, .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanecarboxamides are described, which exhibit renin-inhibiting properties and could be used as antihypertensive agents in pharmaceutical preparations. The manufacturing procedures described are unsatisfactory in terms of the number of process steps and yields and are not suitable for an industrial process. A disadvantage of these processes is also that the total yields of pure diastereomers that are obtainable are too small.

DOCUMENT-IDENTIFIER: US 6730798 B2

TITLE: Process for the preparation of substituted octanoyl amides

Brief Summary Text (2):

In EP-A-0 678 503, δ -amino- γ -hydroxy- ω -aryl-alkanecarbox-amides are described, which exhibit renin-inhibiting properties and could be used as antihypertensive agents in pharmaceutical preparations. The manufacturing procedures described are unsatisfactory in terms of the number of process steps and yields and are not suitable for an industrial process. A disadvantage of these processes is also that the total yields of pure diastereomers that are obtainable are too small.

DOCUMENT-IDENTIFIER: US 5705658 A

TITLE: Azido containing tetrahydro furan compounds

Abstract Text (1):

.delta.-Amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides of formula I ##STR1## and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive medicinal active ingredients.

Brief Summary Text (1):

The invention relates to .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides of formula I ##STR2## wherein R.sub.1 is hydrogen, hydroxy, lower alkoxy, cycloalkoxy, lower alkoxy-lower alkoxy or free or esterified or amidated carboxy-lower alkoxy,

25. JP408081430A. 18 Apr 95. 26 Mar 96. NEW DELTA-AMINO-GAMMA-HYDROXY-OMEGA-ARYLALKANOIC ACID AMIDE. GOESCHKE, RICHARD, et al. 384/609. C07C235/34; A61K031/16 A61K031/165 A61K031/215 A61K031/27 A61K031/275 A61K031/335 A61K031/34 A61K031/36 A61K031/395 A61K031/40 A61K031/41 A61K031/415 A61K031/44 A61K031/445 A61K031/505 A61K031/535 A61K031/54 C07C235/36 C07C311/30 C07C317/44 C07C323/10 C07D207/27 C07D207/40 C07D211/32 C07D213/40 C07D213/65 C07D233/64 C07D233/76 C07D239/10 C07D257/04 C07D263/38 C07D265/30 C07D271/06 C07D277/18 C07D295/14 C07D295/18 C07D295/22 C07D307/33 C07D317/64 C07D319/20 C07D521/00 C07F007/18 .

☐ 26. EP001692095A1. 30 Nov 04. 23 Aug 06. DELTA-AMINO-GAMMA-HYDROXY-OMEGA-ARYL-ALKANOIC ACID AMIDES AND USE AS RENIN INHIBITORS. SELLNER, HOLGER, et al.

☐ 27. WO2005054177A1. 30 Nov 04. 16 Jun 05. DELTA-AMINO-GAMMA-HYDROXY-OMEGA-ARYL-ALKANOIC ACID AMIDES AND USE AS RENIN INHIBITORS. SELLNER, HOLGER, et al. C07C237/22; A61K031/165.

☐ 28. WO2005051895A1. 25 Nov 04. 09 Jun 05. ORGANIC COMPOUNDS. NOVARTIS, AG, et al. C07C237/20; C07D295/02 C07C237/24 C07C271/24 C07C323/29 C07C255/50 C07D319/18 C07D313/08 C07D307/79 C07D207/09 C07D333/08 A61P009/12 A61K031/165 A61K031/325 A61K031/44.

☐ 29. WO2006069617A. Transition metal-catalyzed asymmetric hydrogenation of acrylic acid derivatives is conducted with hydrogen donors using catalyst system comprising ruthenium, rhodium or iridium and chiral phosphorus ligand or achiral phosphine ligand. BOOGERS, J, et al. B01J031/16 B01J031/18 B01J031/24 B01J031/26 B01J031/28 C07B053/00 C07C051/347 C07C051/36 C07C067/00 C07C067/303.

☐ 30. WO2005058291A. Oral composition useful to treat conditions associated with renin activity (e.g. hypertension), comprising delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amide renin inhibitor in absorption enhancing medium. OTTINGER, I. A61K009/107 A61K031/00 A61K031/165 A61P009/00 A61P009/10 A61P009/12 A61P025/00 A61P027/00 A61P027/06.

☐ 31. WO2005054177A. New delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides useful in the manufacture of medicament for the treatment or prevention of hypertension, congestive heart failure, cardiac hypertrophy or cardiac fibrosis. COTTENS, S, et al. A61K031/165 C07C237/00 C07C237/22.

☐ 32. EP 678500A. New amino-alkanoic acid derivs. - useful as intermediates for hydroxylated amino-alkanoic acid amide renin inhibitors. COHEN, N C, et al. A61K031/16 A61K031/165 A61K031/215 A61K031/27 A61K031/275 A61K031/325 A61K031/33 A61K031/335 A61K031/34 A61K031/36 A61K031/365 A61K031/395 A61K031/40 A61K031/41 A61K031/415 A61K031/42 A61K031/425 A61K031/44 A61K031/445 A61K031/495 A61K031/505 A61K031/535 A61K031/54 A61P003/08 A61P009/00 A61P009/12 A61P013/02 A61P025/20 A61P027/02 A61P043/00 C07C000/00 C07C211/03 C07C213/00 C07C215/06 C07C217/04 C07C219/28 C07C223/02 C07C225/00 C07C225/02 C07C225/16 C07C229/06 C07C229/08 C07C229/10 C07C229/36 C07C233/00 C07C235/34 C07C235/36 C07C237/00 C07C237/02 C07C237/20 C07C237/22 C07C237/24 C07C241/08 C07C255/13 C07C255/16 C07C255/20 C07C255/29 C07C255/60 C07C271/06 C07C271/10 C07C271/16 C07C271/18 C07C271/22 C07C311/09 C07C311/30 C07C311/32 C07C311/46 C07C317/00 C07C317/04 C07C317/18 C07C317/28 C07C317/44 C07C323/10 C07C323/12 C07C323/63 C07C333/02 C07D207/26 C07D207/27 C07D207/273

C07D207/33 C07D207/40 C07D211/12 C07D211/32 C07D211/46 C07D211/88 C07D213/30
C07D213/361 C07D213/40 C07D213/56 C07D213/65 C07D213/89 C07D213/891 C07D233/64
C07D233/70 C07D233/76 C07D233/78 C07D237/20 C07D239/10 C07D239/20 C07D241/08
C07D257/02 C07D257/04 C07D263/02 C07D263/06 C07D263/20 C07D263/22 C07D263/26
C07D263/38 C07D265/06 C07D265/30 C07D265/32 C07D271/06 C07D271/22 C07D273/01
C07D277/14 C07D277/18 C07D277/28 C07D279/12 C07D293/14 C07D294/14 C07D295/04
C07D295/13 C07D295/14 C07D295/15 C07D295/18 C07D295/185 C07D295/22 C07D307/00
C07D307/02 C07D307/32 C07D307/33 C07D317/18 C07D317/58 C07D317/64 C07D319/18
C07D319/20 C07D323/12 C07D401/00 C07D403/00 C07D405/00 C07D405/06 C07D407/06
C07D409/00 C07D409/06 C07D413/02 C07D413/06 C07D413/12 C07D413/14 C07D521/00
C07F007/10 C07F007/18 C07M007:00 C07D263:26 C07D413/06.

[Generate Collection](#)[Print](#)

Term	Documents
(2 OR 1).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	32
(L2 OR L1).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	32

[Prev Page](#)[Next Page](#)[Go to Doc#](#)

DOCUMENT-IDENTIFIER: US 5705658 A

TITLE: Azido containing tetrahydro furan compounds

Abstract Text (1):

.delta.-Amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides of formula I ##STR1## and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive medicinal active ingredients.

Brief Summary Text (1):

The invention relates to .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides of formula I ##STR2## wherein R.sub.1 is hydrogen, hydroxy, lower alkoxy, cycloalkoxy, lower alkoxy-lower alkoxy or free or esterified or amidated carboxy-lower alkoxy,

Brief Summary Text (345):

The pharmaceutical compositions comprise from approximately 1% to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient. Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, dragees, tablets or capsules.

Brief Summary Text (347):

Solutions of the active ingredient, and also suspensions, and especially isotonic aqueous solutions or suspensions, are preferably used, it being possible, for example in the case of lyophilised compositions that comprise the active ingredient alone or together with a carrier, for example mannitol, for such solutions or suspensions to be made up prior to use. The pharmaceutical compositions may be sterilised and/or may comprise excipients, for example preservatives, stabilisers, wetting agents and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers, and are prepared in a manner known per se, for example by means of conventional dissolving or lyophilising processes. The said solutions or suspensions may comprise viscosity-increasing substances, such as sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone or gelatin.

Brief Summary Text (350):

Pharmaceutical compositions for oral administration can be obtained by combining the active ingredient with solid carriers, if desired granulating a resulting mixture, and processing the mixture, if desired or necessary, after the addition of appropriate excipients, into tablets, dragee cores or capsules. They can also be incorporated into plastics carriers that allow the active ingredients to diffuse or be released in measured amounts.

Brief Summary Text (351):

Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and also binders, such as starch pastes using, for example, corn, wheat, rice or potato starch, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above-mentioned starches, also carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate. Excipients are especially flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable, optionally enteric, coatings, there being used, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations,

such as ethylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Capsules are dry-filled capsules made of gelatin and also soft, sealed capsules made of gelatin and a plasticiser, such as glycerol or sorbitol. The dry-filled capsules may comprise the active ingredient in the form of granules, for example with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and if desired with stabilisers. In soft capsules the active ingredient is preferably dissolved or suspended in suitable oily excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols, it likewise being possible for stabilisers and/or antibacterial agents to be added. Dyes or pigments may be added to the tablets or dragee coatings or to the capsule casings, for example for identification purposes or to indicate different doses of active ingredient.

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 10 of 10 returned.**

-
- ☐ 1. [20070049616](#). 23 Aug 06. 01 Mar 07. Organic compounds. Ksander; Gary Michael, et al. 514/303; 514/393 546/119 548/302.7 A61K31/4188 20070101 A61K31/4745 20070101 C07D471/02 20060101
-
- ☐ 2. [20040132148](#). 14 Nov 03. 08 Jul 04. Process for the preparation of substituted carboxylic esters. Herold, Peter, et al. 435/135; 435/136 C12P007/62 C12P007/40.
-
- ☐ 3. [7153675](#). 26 Apr 02; 26 Dec 06. Process for the preparation of substituted carboxylic esters. Herold; Peter, et al. 435/135; 435/136 560/129. C07C69/02 20060101 C12P7/40 20060101 C12P7/62 20060101.
-
- ☐ 4. [5705658](#). 14 Feb 97; 06 Jan 98. Azido containing tetrahydro furan compounds. Goschke; Richard, et al. 549/321; 544/168. C07D307/33.
-
- ☐ 5. [5654445](#). 02 Jul 96; 05 Aug 97. delta-amino-gamma-hydroxy-omega-aryl-alkanoic acids. Goschke; Richard, et al. 549/321; 548/215 554/110. C07D307/33 C07F007/18.
-
- ☐ 6. [5646143](#). 25 Jul 96; 08 Jul 97. delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides. Goschke; Richard, et al. 514/233.8; 544/148 549/362 549/441 554/55. A61K031/335 A61K031/535 C07D317/64 C07D413/12.
-
- ☐ 7. [5627182](#). 25 Jul 96; 06 May 97. delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides. Goschke; Richard, et al. 514/237.8; 514/620 544/168 544/58.2 546/226 548/550 554/43 554/54 554/55 554/58. A61K031/165 A61K031/535 C07C237/20 C07D293/14.
-
- ☐ 8. [5606078](#). 04 Apr 95; 25 Feb 97. 3,5-Disubstituted tetrahydrofuran-2-ones. Goschke; Richard, et al. 549/321; 549/323. C07D307/33.
-
- ☐ 9. [5559111](#). 04 Apr 95; 24 Sep 96. delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides. Goschke; Richard, et al. 514/227.5; 514/620 544/168 544/316 546/216 546/226 546/233 546/337 548/131 548/187 548/204 548/232 548/253 548/319.5 548/338.1 548/546 548/550 554/36 554/37 554/42 554/45. A61K031/165 A61K031/54 C07D237/20 C07D294/14.
-
- ☐ 10. [WO2005058291A](#). Oral composition useful to treat conditions associated with renin activity (e.g. hypertension), comprising delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amide renin inhibitor in absorption enhancing medium. OTTINGER, I. A61K009/107 A61K031/00 A61K031/165 A61P009/00 A61P009/10 A61P009/12 A61P025/00

DERWENT-ACC-NO: 2005-479200

DERWENT-WEEK: 200706

COPYRIGHT 2007 DERWENT INFORMATION LTD

TITLE: Oral composition useful to treat conditions associated with renin activity (e.g. hypertension), comprising delta-amino-gamma-hydroxy-omega-aryl-alka- noic acid amide renin inhibitor in absorption enhancing medium

INVENTOR: OTTINGER, I

PRIORITY-DATA: 2004US-547676P (February 25, 2004), 2003US-531562P (December 19, 2003)

[Search Selected](#)[Search ALL](#)[Clear](#)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<input type="checkbox"/> MX 2006006926 A1	September 1, 2006		000	A61K031/00
<input type="checkbox"/> WO 2005058291 A1	June 30, 2005	E	027	A61K031/00
<input type="checkbox"/> AU 2004298758 A1	June 30, 2005		000	A61K009/107
<input type="checkbox"/> EP 1729748 A1	December 13, 2006	E	000	A61K031/00

INT-CL (IPC): A61K 9/107; A61K 31/00; A61K 31/165; A61P 9/00; A61P 9/10; A61P 9/12; A61P 25/00; A61P 27/00; A61P 27/06

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)